|
||||||||||||
Welcome to the AMS Newsletter for doctors and other healthcare professionals who have a special interest in women's health. The content covers information and resources relevant to menopause, midlife and the promotion of healthy ageing.
Â
In this edition{tableofcontents|type:h3}
Â
October 2023Management of menopauseBy Dr Karen Magraith and Dr Christina Jang The article is available free online from the Australian Prescriber, Issue 3 October 2023 Article Summary During perimenopause and after menopause, women may experience diverse symptoms. All women require a comprehensive assessment of their current health and risks for future disease, appropriate screening, and promotion of a healthy lifestyle. Menopausal hormone therapy is the most effective treatment for menopausal symptoms. It can be offered to symptomatic patients with no contraindications following an individualised discussion about the risk of harms versus benefits. Menopausal hormone therapy is recommended for women with premature ovarian insufficiency (menopause occurring before 40 years of age) regardless of symptoms, unless contraindicated. Nonhormonal medications may improve symptoms for women who have contraindications to, or do not wish to take, menopausal hormone therapy. Reference Magraith K, Jang C. Management of menopause. Aust Prescr 2023;46:48–53. doi.org/10.18773/austprescr.2023.014 The impact of symptoms attributed to menopause by Australian womenAMS was invited by Jean Hailes for Women’s Health to co-author the report The impact of symptoms attributed to menopause by Australian Women from the results of the 2023 Jean Hailes National Women’s Health Survey. AMS was able to add some valuable input to this report including:
Menopause Essentials Update | 4 November 2023, Perth WAJoin us for lunch followed by an update on the essentials of menopause management. This workshop is aimed at GPs, gynaecologists, endocrinologists and other health professionals who are seeking a comprehensive review of the current issues that face them in the diagnosis and management of menopausal symptoms. Presentations will include case studies and there will be time for questions. Topics include:
Download flyer here:  AMS members: free AMS non-members: $100 (GST inc) Register Go to Trybooking at: www.trybooking.com/CLOZA Continuing Education RACGP 3 CPD Hours ACRRM 3 points Updated Information Sheets: AMS Guide to MHT/HRT DosesThe AMS Guide to MHT/HRT Doses for both Australia and New Zealand have now been updated and are available on the AMS website. AMS Guide to MHT/HRT Doses Australia only AMS Guide to MHT/HRT Doses New Zealand only Dr Christina Jang Survey for IMS 2016 Recommendations UpdateThe IMS is updating the 2016 Recommendations on Midlife Women’s Health. Two surveys have been developed by the IMS and Monash University to understand women’s needs about the topics to be included in the updated Recommendations and the accompanying tools/resources. One survey is for midlife women aged 45-65 and one is for health professionals. For Health ProfessionalsFor WomenIMS World Congress on Menopause in Melbourne 2024Health Professionals - join AMS for Members-only contentÂIMS Live 16 October 2023: Vaginal laser therapy for GSM/VVA: where we stand now - a review by the EUGA Working Group on Laser IMS Live 23 October 2023: Understanding the brain during menopause Life Expectancy and Major Chronic Diseases - video Our Menopause World October 2023 Newsletter European Menopause and Andropause Society (EMAS) Newsletter |
||||||||||||
![]() |
||||||||||||
![]() |
||||||||||||
![]() |
||||||||||||
Copyright © 2023 Australasian Menopause Society Ltd. PO Box 280, Healesville, VIC 3777 Tel: +61 3 5962 6241 | Email: ams@menopause.org.au ![]() ![]() ![]() ![]() |
||||||||||||
Health Professionals join the AMS now |
||||||||||||
Contact us | Unsubscribe |